Male breast cancer: A retrospective analysis |
| |
| Authors: | A Yoney A Kucuk M Unsal |
| |
| Institution: | 1. Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal;2. European Organisation for Research and Treatment of Cancer-Breast Cancer Group, Toronto, Canada;3. Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Canada;4. University of Edinburgh, Edinburgh, UK;5. European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium;6. Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands;7. Dutch Breast Cancer Research Group (BOOG), The Netherlands;8. Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA;9. Department of Pathology, University of Washington, Seattle, USA;10. Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden;11. Swedish Association of Breast Oncologists (SABO), Lund University, Lund, Sweden;12. Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden;13. Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands;14. Breast Cancer Genomics and Proteomics Lab, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands;15. Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Canada;16. Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands;17. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York;18. Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York;19. Weill Cornell Medical College, New York;20. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, USA;21. Department of Medical Oncology, Hospital Network Antwerp (ZNA), Antwerp, Belgium;22. Department of General Medical Oncology, UZ Leuven, Leuven, Belgium;23. Beatson West of Scotland Cancer Centre, Glasgow, UK;24. Specialist Hospital, St. Wojciech, Gdansk, Poland;25. Breast Surgical Unit, Hospital Universitario Vall d’Hebron, Barcelona, Spain;26. Swiss Group for Clinical Cancer Research (SAKK), Switzerland;27. All Ireland Cooperative Oncology Research Group (ICORG), Ireland;28. Department of Oncology, Mayo Clinic, Rochester, USA;29. Dana-Farber Cancer Institute, Boston, USA;30. Department of Oncology, Västmanlands Hospital, Västerås, Sweden;31. Swedish Association of Breast Oncologists (SABO), Sweden;32. Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium;33. University of Washington, Seattle, USA;34. Department of Oncology, Cheltenham General Hospital, UK;35. Global Academic Programs, University of Texas MD Anderson Cancer Center, Houston, USA;36. Breast International Group, Brussels, Belgium;37. Departments of Health Services Research and Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA |
| |
| Abstract: | BackgroundTo evaluate our results in the treatment of male breast cancer patients with respect to local control (LC), overall survival (OS) and possible prognosis factors for survival.Patients and methodsThirty-nine patients with male breast cancer have been retrospectively studied with the trial aim to evaluate the results of our practice. Among them, 94.8% had invasive ductal carcinoma (IDC), 2.6% invasive papillary carcinoma (IPC) and 2.6% invasive lobular carcinoma (ILC) and the distribution according to stage was found to be 12.8, 46.2, 30.7 and 10.3% in Stages I, II, III and IV, respectively. Among the patients, 7.7% received radiotherapy (RT) and hormonotherapy (HT), 22.8% received chemotherapy (CT), 61.8% received chemoradiotherapy (CRT) and HT and 7.7% received HT in addition to surgery.ResultsThe distant metastases rate was 36% and the local recurrence rate was 5%. All the local recurrences and the distant metastases had occurred after the first two years. The five-year disease free survival (DFS) and OS rates were 65.8 and 80.1% respectively. In our series, univariate analysis for OS demonstrated statistical significance for lymph node metastases (p = 0.00001), stage (p = 0.0098) and age (p = 0.03); while RT in the treatment modality (p = 0.6849), and tumor size (p = 0.4439) demonstrated no significance. The presence of lymph node metastases significantly impairs OS (p = 0.004) and DFS (p = 0.014) in multivariate analysis.ConclusionPostoperative radiotherapy was important in the management of male breast cancer to improve LC resulting in one local failure, but did not improve OS and DFS in our analysis. The presence of lymph node metastases significantly impaired OS and DFS. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
